quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·24d
PRRelease
Aurinia Pharmaceuticals Inc logo
Kezar Life Sciences Inc. logo

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

AUPH· Aurinia Pharmaceuticals IncKZR· Kezar Life Sciences Inc.
Health Care
Original source

Companies

  • AUPH
    Aurinia Pharmaceuticals Inc
    Health Care
  • KZR
    Kezar Life Sciences Inc.
    Health Care

Recent analyst ratings

  • Dec 3AUPHUpdateLeerink Partners$16.00
  • Nov 7AUPHUpdateJefferies$21.00
  • Nov 5AUPHUpdateRBC Capital Mkts$15.00
  • Oct 17KZRUpdateJefferies$7.00
  • Oct 17KZRUpdateWilliam Blair-
  • Jul 30AUPHUpdateH.C. Wainwright$17.00

Related

  • SEC2d
    SEC Form DEF 14A filed by Aurinia Pharmaceuticals Inc
  • SEC9d
    SEC Form SC 14D9 filed by Kezar Life Sciences Inc.
  • SEC10d
    SEC Form SC TO-T filed by Kezar Life Sciences Inc.
  • SEC17d
    SEC Form SCHEDULE 13G filed by Kezar Life Sciences Inc.
  • SEC20d
    SEC Form SC14D9C filed by Kezar Life Sciences Inc.
  • SEC20d
    Aurinia Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC20d
    Kezar Life Sciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
  • INSIDER21d
    SEC Form 3 filed by new insider Cole Ryan
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022